Hasil Pencarian  ::  Simpan CSV :: Kembali

"Background: the use of statin to lower blood cholesterol is often associated with bothersome adverse effects such as myopathy and liver dysfunction. NC120 is herbal lipid lowering drug containing red yeast rice (RYR) extract, guggulipid, and chromium picolinate, and expected to have better safety profile. The aim of this study was to evaluate the efficacy and safety profiles of NC120 in lowering blood lipid. Methods: this was a double blind randomized clinical trial comparing NC120 with placebo in subjects with hypercholesterolemia. Two capsules of NC120 or placebo were administered twice a day for 28 days. Blood total-cholesterol, LDL-cholesterol, and triglyceride were measured on day-0, day-7, and day-28. Unpaired t-test was used to compare study parameter between groups, and one-way ANOVA was used to compare within group. Results: 25 subjects received NC120 and 24 subjects received placebo. Significant decrease of total cholesterol and LDL-cholesterol were observed since day-7 in NC120 group, while the changes in placebo group were not significant at all time of observation. No significant decrease of triglyceride was observed in NC120 group and in placebo group. Side effects were minor and comparable between the two groups. Conclusion: NC120 is effective in reducing total cholesterol and LDL-cholesterol, but not triglyceride. This drug shows a good safety profile, and thus can be considered for patients who can not tolerate statin drugs."

"Background: Glucosamine, chondroitinsulfate are frequently used to prevent further joint degeneration in osteoarthritis (OA). Methylsulfonylmethane (MSM) is a supplement containing organic sulphur and also reported to slow anatomical joint progressivity in the knee OA. The MSM is often combined with glucosamine and chondroitin sulfate. However, there are controversies whether glucosamine chondroitin sulfate or their combination with methylsulfonylmethane could effectively reduce pain in OA. This study is aimed to compare clinical outcome of glucosamine chondroitin sulfate (GC), glucosamine chondroitin sulfate methylsulfonylmethane (GCM), and placeboin patients with knee osteoarthritis (OA) Kellgren Lawrence grade I II. Methods: a double blind, randomized controlled clinical trial was conducted on 147 patients with knee OA Kellgren Lawrence grade I II. Patients were allocated by permuted block randomization into three groups: GC (n=49), GCM (n=50), or placebo (n=48) groups. GC group received 1500 mg of glucosamine + 1200 mg of chondroitin sulfate + 500 mg of saccharumlactis; GCM group received 1500 mg of glucosamine + 1200 mg of chondroitin sulfate + 500 mg of MSM; while placebo group received three matching capsules of saccharumlactis. The drugs were administered once daily for 3 consecutive months VAS and WOMAC scores were measured before treatment, then at 4th, 8th and 12th week after treatment. Results: on statistical analysis it was found that at the 12th week, there are significant difference between three treatment groups on the WOMAC score (p=0.03) and on the VAS score (p=0.004). When analyzed between weeks, GCM treatment group was found statistically significant on WOMAC score (p=0.01) and VAS score (p<0.001). Comparing the score difference between weeks, WOMAC score analysis showed significant difference between GC, GCM, and placebo in week 4 (p=0.049) and week 12 (p=0.01). In addition, VAS score also showed significant difference between groups in week 8 (p=0.006) and week 12 (p<0.001). Conclusion: combination of glucosamine chondroitinsulfate methylsulfonylmethane showed clinical benefit for patients with knee OAK ellgren Lawrence grade I II compared with GC and placebo. GC did not make clinical improvement in overall groups of patients with knee OA Kellgren Lawrence grade I II."

"ABSTRACTBACKGROUND: Alphacalcidol, a vitamin D analog, shows immune regulatory potency as it works on the macrophage and T cell to control inflammation and T cell dysregulation in elderly. None has been known about its effect on elderly with various states of frailty syndrome, which have different level of chronic low grade inflammation. This study aimed to determine the effect of alphacalcidol on inflammatory cytokines (IL-6, IL-10, g-IFN ) and T cell subsets (CD4/CD8 ratio and CD8+ CD28-) of elderly with various stages of frailty syndrome. METHODS: from January to July 2017, a double blind randomized controlled trial (RCT) with allocation concealment, involving 110 elderly subjects from Geriatric Outpatient Clinic Cipto Mangunkusumo Hospital Jakarta, was conducted to measure the effect of 0.5 mcg alphacalcidol administration for 90 days to inflammatory cytokines (IL-6, IL-10, g-IFN) from PBMC culture supernatant, as well as CD4/CD8 and CD8+CD28- percentage using flow cytometry. Statistical analysis using SPSS version 20 was performed with t-test to measure mean difference. RESULTS: of 110 subjects involved in the RCT consisting of 27 fit, 27 pre-frail and 56 frail elderly, 25(OH)D serum level was found to be as low as 25.59 (12.2) ng/ml in alphacalcidol group and 28.27 (10.4) ng/ml in placebo group. Alphacalcidol did not decrease IL-6 (p=0.4) and g- IFN (p=0.001), but it increased IL-10 (p=0,005) and decreased IL6/IL10 ratio (p=0.008). Alphacalcidol increased CD4/CD8 ratio from 2.68 (SD 2.45) to 3.2 (SD 2.9); p=0.001 and decreased CD8+ CD28- percentage from 5.1 (SD 3.96) to 2.5 (1.5); p<0.001. Sub group analysis showed similar patterns in all frailty states. CONCLUSION: Alphacalcidol improves immune senescence by acting as anti-inflammatory agent through increased IL-10 and decreased IL6/IL-10 ratio and also improves cellular immunity through increased CD4/CD8 ratio and decreased CD8+ CD28- subset in elderly. This effect is not influenced by frailty state."

"Latar belakang: Pitiriasis versikolor (PV) merupakan infeksi jamur superfisial kronik dengan prevalensi tinggi. Belum ada data yang membandingkan sampo SeS2 1,8% dengan ketokonazol 2% pada terapi PV. Tujuan: Mengetahui efikasi mikologis, keamanan, kekambuhan, dan efikasi biaya antara sampo selenium sulfida 1,8% dibandingkan dengan ketokonazol 2% pada PV. Metode: Uji klinis acak tersamar ganda terhadap pasien PV bulan September hingga Desember 2018, dengan terapi sampo SeS2 1,8% atau ketokonazol 2% sesuai dengan alokasi random. Dilakukan pemeriksaan fisik, uji provokasi skuama, lampu Wood, dan kalium hidroksida. Efikasi mikologis dianalisis dengan intention to treat dan kekambuhan dengan analisis per-protokol. Efikasi biaya dengan menghitung Incremental Cost-Effectiveness Ratio (ICER). Hasil: Efikasi mikologis lebih tinggi pada ketokonazol 2%, yaitu sebesar 94% vs 86%, tetapi tidak berbeda secara statistik (RR=2,3(95%IK0,6-8,5), p=0,182). Efek samping pada ketokonazol 2% lebih tinggi, yaitu 22% vs 8%. SeS2 1,8% lebih murah 14.880 rupiah, dengan risiko KOH masih positif sebesar 8% lebih tinggi dibanding ketokonazol 2%. Kekambuhan sebulan didapatkan lebih besar pada SeS2 1,8%, yaitu sebesar 8% vs 14%. Kesimpulan: Tidak terdapat perbedaan efikasi mikologis, efek samping, dan kekambuhan sebulan, antara SeS2 1,8% dengan ketokonazol 2%. Penggunaan SeS2 1,8% pada terapi PV lebih murah dengan risiko gagal terapi lebih tinggi dibandingkan ketokonazol 2%.

---

Background: Pityriasis versicolor (PV) is a chronic superficial fungal infection which highly prevalent. There is no data comparing SeS2 1.8% with 2% ketoconazole shampoo in the treatment of PV. Objective: To assess the mycological efficacy, safety, relaps, and cost-efficacy of SeS2 1.8% and ketoconazole 2% shampoo for the treatment of PV. Methods: A double blind randomized controled trial was performed in patients with PV during September-December 2018, based on block randomization. Physical examinations, scale provocation test, Woods lamp and potassium hydroxide examination were conducted. Intention to treat analysis was performed to evaluated mycological efficacy and per-protocol analysis to evaluated relaps. Cost-efficacy was analyzed by calculating the Incremental Cost-Effectiveness Ratio (ICER). Result: The mycological efficacy, side effect and relaps were higher in the ketoconazole group; 94% vs 86% (RR=2.3(95%CI 0.6-8.5), p= 0.182), 22% versus 8%, and 14% versus 8%. We found lesser cost for SeS2 1.8% of about 14.880 rupiah with risk of persistent positive KOH smear is 8% higher than ketoconazole. Conclusion: There were no significant differences of mycological efficacy, side effect, and relaps, between both arms. The cost-efficacy revealed a lesser cost for SeS2 1.8% with higher risk of persistent positive KOH as compared to ketoconazole."

"ABSTRAKLatar belakang: Xerosis kutis sering ditemukan pada lanjut usia lansia . Aplikasi pelembap merupakan tatalaksana utama. Pelembap mengandung humektan, misalnya laktat dan urea, dapat memperbaiki hidrasi dan disfungsi sawar kulit. Penelitian ini bertujuan untuk membandingkan efikasi dan keamanan antara krim pelembap yang mengandung amonium laktat 12 dan urea 10 dalam mengatasi xerosis kutis pada populasi lansia. Metode: Penelitian uji klinis acak tersamar ganda dengan subjek kelompok berpasangan dilakukan pada 40 orang penghuni panti werdha di Jakarta. Evaluasi specified symptom sum score SRRC , skin capacitance SCap , transepidermal water loss TEWL , dan efek samping dilakukan pada awal terapi, minggu kedua dan keempat terapi, serta minggu kelima seminggu setelah terapi dihentikan. Hasil: Penurunan nilai SRRC dan TEWL, peningkatan nilai SCap, setelah empat minggu tidak berbeda bermakna antara kedua kelompok terapi dengan nilai p masing-masing 1,000; 0,636; dan 0,601. Pada minggu kelima, terjadi peningkatan nilai SRRC dan TEWL serta penurunan nilai SCap minggu keempat pada kedua kelompok, namun masih lebih baik daripada nilai dasar dan minggu kedua terapi. Tidak ditemukan efek samping subjektif dan objektif pada kedua kelompok. Kesimpulan: Efikasi dan keamanan krim pelembap yang mengandung amonium laktat 12 sama baiknya dengan krim pelembap yang mengandung urea 10 dalam mengatasi xerosis kutis pada populasi lansia. Kata kunci: amonium laktat 12 ; lanjut usia; urea 10 ; xerosis kutis

---

ABSTRACTBackground Xerosis cutis is widely known in geriatric population. Application of moisturizer is the treatment.. Moisturizer with humectant property, e.g lactate and urea, could restore skin hydration and barrier dysfunction. This study aims to compare the efficacy and safety between moisturizing cream containing 12 ammonium lactate and 10 urea in geriatric population with xerosis cutis. Methods A double blind randomized controlled trial with matching paired subject was conducted on 40 residents of a nursing home in Jakarta. Evaluation of specified symptom sum score SRRC , skin capacitance SCap , transepidermal water loss TEWL , and side effects were measured at baseline, week 2 and week 4 after therapy, and week 5 one week after therapy cessation. Results The decrease of SRRC and TEWL score, increase of SCap score after four weeks of therapy between two group yield no statistical different p 1.000 p 0.636 p 0.601 respectively . On the fifth week, SRRC and TEWL score were increased and SCap score was decreased compared to the fourth week, but they are still better than the score on baseline and the second week. No objective and subjective side effects were found. Conclusions The efficacy and safety of moisturizing cream containing 12 ammonium lactate are the same as 10 urea in treating xerosis cutis of geriatric population. Keywords 12 ammonium lactate 10 urea geriatric xerosis cutis"

"scleroderma is an autoimmune disease characterized by organ fibrosis, resistant to standard treatment. It is suspected the addition of Physalis angulata Linn. (Ciplukan) extract as adjuvant therapy can improve the scleroderma skin fibrosis. The aim at this study is to evaluate the effect of ciplukan extract as adjuvant on scleroderma skin fibrosis in standard therapy, based on modified Rodnan skin scale (MRSS), inflammatory biomarkers, immunology and serum fibrosis. Methods: double-blind, randomized clinical trial was performed in scleroderma patients with stable disease at Cipto Mangunkusumo hospital and Hasan Sadikin hospital during November 2015−March 2017 who met the selection criteria and continued to receive standard therapy. The subjects were randomly allocated into two groups: the study group received the ciplukan extract 3 x 250 mg / day for 12 weeks and the placebo group. Examination of MRSS, ESR, P1NP, BAFF and sCD40L was performed every 4 weeks until the end of the study. Results: fifty-nine subjects completed the study. They consisted of 29 subjects of the treatment group and 30 of the placebo group, with an average age of 41 (SD 9) years, the proportion of women: male = 9 : 1. There was a significant improvement of skin fibrosis in the study group with a highly significant decrease in MRSS (35.9% VS 6.3%, p <0.001) and a relative decrease in P1NP levels (17.8% VS 0.7%, p = 0.002). No decrease in ESR, BAFF and sCD40L levels in both groups. There was a weak but significant positive correlation between MRSS with P1NP levels (r = 0.236, p = 0.036). Conclusion: Ciplukan extract with dose 3 x 250 mg for 12 weeks as adjuvant on scleroderma standard therapy alleviates skin fibrosis significantly based on MRSS and P1NP levels."

"Rhinos® SR adalah kapsul kombinasi tetap loratadin 5 mg dengan pseudoefedrin 60 mg lepas cepat dan pseudoefedrin 60 mg lepas lambat. Studi ini bertujuan untuk menilai efikasi Rhinos® SR pada nasal airway resistance (NAR) secara obyektif dengan rhinomanometer dan gejala-gejala nasal serta nonnasal pada pasien dengan rinitis alergik sepanjang tahun (RAST) di negara tropis. Ini adalah studi paralel berpembanding plasebo, acak, tersamar ganda, dilakukan pada 59 pasien RAST berobat jalan di klinik THT RS Umum Dr. Soetomo, Surabaya. Pasien laki-laki dan perempuan, menderita RAST sedang sampai berat minimal 2 tahun, berumur 12 tahun ke atas, dengan total skor gejala nasal (TSGN) > 6 dan skor kongesti nasal (SKN) > 2, mendapat Rhinos® SR atau plasebo 2 kali sehari selama 7 hari. Parameter efikasi yang utama adalah berkurangnya nilai-nilai NAR (yang diukur dengan rhinomanometer pada hari pertama) dari Rhinos® SR dibandingkan dengan plasebo. Nilai-nilai NAR dihitung sebagai luas area di bawah kurva (area under the curve = AUC) dari NAR terhadap waktu. Parameter efikasi sekunder adalah berkurangnya gejala-gejala klinik (nasal dan nonnasal) yang dinilai oleh pasien maupun oleh dokter peneliti setelah 1 minggu penggunaan Rhinos® SR atau plasebo. Dari 59 pasien yang memenuhi syarat, semuanya menyelesaikan studi 1 minggu ini. Untuk nilai-nilai NAR, setelah baseline disamakan menjadi 100%, AUC0-10 jam tidak berbeda bermakna antara Rhinos® SR dan plasebo. Akan tetapi waktu pseudoefedrin mencapai kadar puncak, yakni 2 jam untuk yang lepas cepat dan 6 jam untuk yang lepas lambat, maka AUC0-2 jam dan AUC0-6 jam Rhinos® SR lebih rendah secara bermakna dibandingkan dengan plasebo. TSGN berdasarkan penilaian penderita (jumlah skor 3 pagi terakhir) untuk Rhinos® SR menurun 33.0% dari skor awal (p < 0.001), untuk plasebo juga menurun 21.9% dari skor awal (p = 0.002), tetapi penurunan oleh Rhinos tidak berbeda bermakna dengan penurunan oleh plasebo. Penurunan TSGN berdasarkan penilaian dokter peneliti, serta penurunan skor kongesti nasal (SKN) dan total skor gejala (nasal dan nonnasal), dan bahkan skor masing-masing gejala, berdasarkan penilaian pasien maupun dokter peneliti, menunjukkan pola yang sama, yakni Rhinos® SR dan plasebo menurunkan gejala secara bermakna dari nilai awal, dan penurunan oleh Rhinos® SR lebih besar dibandingkan penurunan oleh plasebo tetapi tidak berbeda bermakna. Dalam studi ini tidak ditemukan efek samping. Dari penelitian ini disimpulkan bahwa pada pasien RAST sedang sampai berat di negara tropis, Rhinos® SR efektif dalam mengurangi kongesti nasal dengan pengukuran obyektf NAR. Rhinos® SR 2 x sehari selama 7 hari juga efektif dalam mengurangi gejala-gejala klinik RAST meskipun tidak mencapai kemaknaan statistik dibandingkan dengan plasebo, serta dapat ditoleransi dengan baik.

---

AbstractRhinos® SR is a fixed combination of 5 mg loratadine and 60 mg pseudoephedrine immediate release and 60 mg pseudoephedrine sustained release. The present study was aimed to assess the efficacy of Rhinos® SR on nasal airway resistance (NAR) objectively using rhinomanometer and on nasal symptoms in patients with perennial allergic rhinitis (PAR) in a tropical country. This was a randomized, double-blind, parallel group study in 59 PAR patients who visited the ENT clinic at Dr. Soetomo General Hospital, Surabaya. Outpatients of both gender, having moderate to severe PAR for a minimal of 2 years, aged 12 years or older, with a total nasal symptom score (TNSS) > 6 and a nasal congestion score > 2, received Rhinos® SR or placebo twice daily for 7 days. The primary efficacy parameter was the decrease in the NAR values (measured by rhinomanometer on Day 1) of Rhinos® SR from those of placebo. The NAR values were calculated as the area under the curve (AUC) of NAR versus time. The secondary efficacy parameters were the percentage reduction of the clinical symptoms (nasal and nonnasal) evaluated by both the patient and the physician after 1 week use of Rhinos® SR or placebo. From 59 eligible patients, all completed this 1-week trial. For NAR values, after the baseline were considered as 100%, the AUC0-10 h were not significantly different between Rhinos® SR and placebo. However, as the pseudoephedrine reached its peak concentration, i.e. 2 hrs for the immediate release and 6 hrs for the sustained release, then AUC0-2 h and AUC0-6 h of Rhinos® SR were significantly lower compared to those of placebo. Total nasal symptom score (TNSS) evaluated by the patient (sum of the last 3 mornings) for Rhinos® SR decreased 33.0% from baseline (p < 0.001), for placebo decreased 21.9% from baseline (p = 0.002), but the decrease by Rhinos® SR was not significantly different from the decrease by placebo. TNSS evaluated by the physician, nasal congestion score (NCS) and total symptom score (TSS, total nasal and nonnasal), and even the individual symptom scores, evaluated by the patient and the physician, showed similar pattern, i.e. both Rhinos® SR and placebo decreased the symptoms significantly from baseline, and the decreases by Rhinos® SR were larger than the decreases by placebo, but the decreases by Rhinos® SR and placebo were not statistically different. No adverse event was found in this study. From the present study it was concluded that in patients with moderate to severe PAR in a tropical country, Rhinos® SR was effective in relieving nasal congestion by objective measurements of NAR. Rhinos® SR twice a day for 7 days was also effective in reducing the clinical symptoms of PAR although the reductions did not reach statistical significance compared to those by placebo, and was well tolerated. "

"Merokok dapat meningkatkan angka morbiditas dan mortalitas.World Health Organization (WHO) memprediksi pada tahun 2020 penyakit yang disebabkan oleh rokok akan menyebabkan kematian sebanyak 8.4 juta orang di dunia dan setengahnya berasal dari Asia. Varenicline, sebagai agonis parsial reseptor α4β2 nikotin asetilkolin, memiliki potensi yang cukup baik pada program berhenti merokok dengan cara melepaskan withdrawal effect dari nikotin dan menurunkan kebutuhan akan nikotin. METODE. Uji acak tersamar ganda antara bulan Juli 2012 sampai dengan Desember 2012 dengan 12 minggu waktu terapi dan 12 minggu waktu pengamatan status merokok. 80 laki-laki perokok yang bersedia mengikuti penelitian dibagi kedalam kelompok varenciline dan kelompok plasebo.Varenicline dititrasi hingga 2x1 mg (n=40) dan plasebo (n=40) ditambah konseling mingguan. HASIL. Pada pengamatan 4 minggu (minggu 1-4) setelah 12 minggu terapi menunjukkan 55% peserta kelompok varenicline berhenti merokok dibandingkan kelompok plasebo sebesar 27,5%. (Prevalence Ratio [PR] 2,0). Pada pengamatan minggu ke 5-8, 52.5% peserta pada kelompok varenicline masih berhenti merokok dibandingkan dengan 20% pada kelompok plasebo (PR, 2,6). Pada pengamatan minggu 9-12, 47,5% peserta pada kelompok varenicline masih berhenti merokok dibandingkan 17,5% pada kelompok plasebo (PR, 2,7). Rerata hari pertama bebas rokok pada kelompok varenicline adalah 40,63 hari, sedangkan pada kelompok plasebo 56,43 hari. Efek samping yang paling banyak pada penggunaan varenicline adalah mual yang terdapat pada 9 peseerta (22,5%). Rerata kadar CO awal adalah 18,46 ppm, rerata Fagerstrom test untuk ketergantungan nikotin adalah 6,4 dan rerata indeks Binkman adalah 317,9. KESIMPULAN. Varenicline memiliki efikasi yang baik, aman dan dapat ditoleransi baik sebagai farmakoterapi program berhenti merokok.

---

Smoking has increased risk of morbidity and mortality. World Health Organization predicts that by 2020, disease caused by smoking will result in the deaths of around 8.4 million people in the world and half of these deaths from Asia. Varenicline, a partial agonist at the α4β2 nicotinic acetylcholine receptor, has the potential to aid smoking cessation by relieving nicotine withdrawal symptoms and reducing the rewarding properties of nicotine.

METHOD. A randomized, single-blind, placebo controlled trial conducted between July 2012 and December 2012 with a 12 week treatment period and 12 week follow-up of smoking status. 80 male adult smokers who volunteered for the study divide into varenicline and placebo group. Varenicline titrated to 1 mg twice daily (n=40) or placebo (n=40) for 12 weeks, plus weekly smoking cessation counseling.

RESULT. During 4 weeks (weeks 1-4) after 12 weeks of treatment, 55% of participants in the varenicline group were continuously abstinent from smoking compared with 27.5% in the placebo group (Prevalence Ratio [PR] 2,0). For weeks 5 through 8, 52.5% of participants in the varenicline group were continuously abstinent compared with 20% in the placebo group (PR, 2,6). For weeks 9-12, 47.5% of participants in the varenicline group were continuously abstinent compared with 17.5% in the placebo group (PR, 2,7). Mean of first day free of smoking used Varenicline for smoking cessation was 40,63 days and mean of first day free of smoking used placebo was 56.43 days. The most adverse event with varenicline was nausea, which occurred in 9 Participants (22,5%). Mean of CO level was 18,46 ppm, mean of Fagerstrom score for nicotine dependence was 6,4, and mean of Brinkman index was 317,9.

CONCLUSION. Varenicline is an efficacious, safe, and well-tolerated smoking cessation pharmacotherapy."

"Background: sarcopenia contributes to the development of frailty syndrome. Frailty syndrome is potentially improved by modifying insulin resistance, inflammation, and myostatin level. This study is aimed to investigate the effect of metformin on handgrip strength, gait speed, myostatin serum level, and health related quality of life (HR-QoL) among non diabetic pre frail elderly patients.Methods: a double blind randomized controlled trial study was conducted on non-diabetic elderly outpatients aged >60 years with pre frail status based on phenotype and/ or index criteria (Cardiovascular Health Study and/ or Frailty Index 40 items) consecutively recruited from March 2015 to June 2016 at Cipto Mangunkusumo Hospital. One hundred twenty subjects who met the research criteria were randomized and equally assigned into 3 x 500 mg metformin or placebo group. The study outcomes were measured at baseline and after 16 weeks of intervention.Results: out of 120 subjects, 43 subjects in metformin group and 48 subjects in placebo group who completed the intervention. There was a significant improvement on the mean gait speed of metformin group by 0.39 (0.77) second or 0.13 (0.24) meter/second that remained significant after adjusting for important prognostic factors (p = 0.024). There was no significant difference on handgrip strength, myostatin serum level, and HR QoL between both groups.Conclusion: 3 x 500 mg metformin for 16 weeks was statistically significant and clinically important in improving usual gait speed as one of the HR QoL dimensions, but did not significantly improve the EQ 5D index score, handgrip strength, nor myostatin serum level."

"Bedah kimia trichloroacetic acid (TCA) memiliki efek samping yang lebih banyak dibandingkan larutan bedah kimia lainnya. Penelitian ini bertujuan untuk menilai efektivitas pelembap dalam mengurangi efek samping pasca-bedah kimia TCA. Penelitian ini merupakan uji klinis acak terkontrol tersamar ganda dengan metode split face yang dilakukan di Poliklinik Dermatologi dan Venereologi Rumah Sakit dr. Cipto Mangunkusumo. Penilaian global peneliti (PGP), penilaian subjektif pasien (PSP), pemeriksaan indeks eritema (IE), transepidermal water loss (TEWL), dan skin capacitance (SCap) dilakukan pada hari ke-0, 3, dan 7. Subjek penelitian (SP) merupakan wanita dengan diagnosis penuaan kulit (rata-rata usia 46,7 tahun). Sebanyak 27 SP dirandomisasi untuk mendapatkan krim intervensi (krim campuran ekstrak spent grain wax, argan oil, dan shea butter) atau krim vehikulum pada salah satu sisi wajah pasca-tindakan bedah kimia TCA 15%. Terdapat penurunan nilai PGP, PSP, kadar TEWL, dan IE pada kelompok intervensi pada hari ke-3 dan 7 dibandingkan dengan kelompok vehikulum, namun tidak signifikan secara statistik. Kadar SCap meningkat signifikan pada hari ke-7 pada pasien yang mendapat krim intervensi dibandingkan dengan krim vehikulum. Tidak ada efek samping obat yang dilaporkan pada penelitian ini. Krim campuran ekstrak spent grain wax, argan oil, dan sheabutter  aman digunakan dan dapat mengurangi efek samping pasca-bedah kimia TCA.

---

TCA chemical peel has more side effects than other chemical peel solutions. This study aims to assess the effectiveness safety of a post-peel cream containing spent grain wax, argan oil, and shea butter in reducing TCA peel side effects. A randomized, placebo-controlled, double-blinded, split face trial on women undergoing TCA 15% chemical peels. Assessment for global investigator assessment (GIA), subject self-assessment (SSA), erythema index, transepidermal water loss (TEWL), and skin capacitance (SCap) was conducted on days 0, 3, and 7. Twenty-seven patients (mean age 46.7 years) were recruited. There were significant improvements in GIA and SSA scores on both groups, but it is not different between the treatment groups. There were erythema index and TEWL improvement on days 3 and 7 compared to baseline, however, there were no differences between groups. The SCap measurement showed significant improvement in skin capacitance on both groups on day 7, but it was better improvement within intervention group. No adverse effects were reported. Cream containing spent grain wax, argan oil, and shea butter showed higher skin capacitance levels but did not significantly affect erythema index, TEWL, clinical and subjective assessments after TCA chemical peeling. "